Very Low Ketogenic Diet and Energy Expenditure
Effect of Very Low Ketogenic Diet on Energy Metabolism in Women With Obesity
1 other identifier
interventional
20
1 country
1
Brief Summary
This study aimed at evaluating the effectiveness of the active phase of a very low-calorie ketogenic diet in females with obesity lasting 28 days on body weight, body composition and energy metabolism using a metabolic chamber.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jun 2022
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 16, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 16, 2024
CompletedFirst Submitted
Initial submission to the registry
January 23, 2024
CompletedFirst Posted
Study publicly available on registry
February 9, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
March 16, 2025
CompletedJune 4, 2025
May 1, 2025
1.6 years
January 23, 2024
May 28, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
measure of energy expenditure
measures of energy expenditure (in kilocalories) will be assessed by using the metabolic chamber, 24-hour whole room indirect calorimeter. Thus, the measures will be expressed in Kilocalories over 24 hours.
1 month
Study Arms (1)
very low ketogenic diet
EXPERIMENTALpatients with overweight and obesity in treatment for weight loss
Interventions
1 month of active phase of very low ketogenic diet
Eligibility Criteria
You may qualify if:
- overweight and obesity
You may not qualify if:
- Type 1 and type 2 diabetes mellitus
- endocrine disorders
- asthma or pulmonary conditions
- cardiovascular disease
- gastrointestinal disease
- liver disease
- kidney diseases
- anemia (hemoglobin \< 11 g/dL)
- leucopenia (white blood cells \< 4,000/mcL)
- thrombocytopenia (platelets \< 150,000/mcL)
- central nervous system disorders
- neurodegenerative diseases
- psychiatric disorders
- eating disorders
- alcohol abuse and substance dependence
- +2 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University Hospital of Pisa, Endocrinology Unit
Pisa, 56124, Italy
Study Officials
- PRINCIPAL INVESTIGATOR
Ferruccio Santini, MD
University of Pisa
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Researcher, PhD, MD
Study Record Dates
First Submitted
January 23, 2024
First Posted
February 9, 2024
Study Start
June 16, 2022
Primary Completion
January 16, 2024
Study Completion
March 16, 2025
Last Updated
June 4, 2025
Record last verified: 2025-05
Data Sharing
- IPD Sharing
- Will not share